Efficacy and safety of liposomal anthracyclines in Phase I/II clinical trials

David S Alberts, Franco M. Muggia, James Carmichael, Eric P. Winer, Mohammad Jahanzeb, Alan P. Venook, Keith M. Skubitz, Edgardo Rivera, Joseph A. Sparano, Nicholas J. Dibella, Simon J. Stewart, John J. Kavanagh, Alberto A. Gabizon

Research output: Contribution to journalArticle

108 Citations (Scopus)

Abstract

Preclinical studies have established the pharmacologic advantages of liposomal anthracyclines, including pharmacokinetic profiles after bolus dosing that resemble continuous infusion of conventional anthracyclines, increased drug concentrations in tumor cells compared with the surrounding tissues, and reduced toxicity relative to conventional anthracycline treatment. Based on these studies, many phase I and phase II clinical trials were conducted to assess the safety and potential activity of liposomal anthracyclines in the management of both solid and hematologic tumors. These studies provided valuable insight into the safety of pegylated liposomal doxorubicin (Doxil/Caelyx [PLD]), nonpegylated liposomal doxorubicin (Myocet [NPLD]), and liposomal daunorubicin (DaunoXome [DNX]) over a range of doses, either as single-agent therapy or in combination with other cytotoxic agents. Other liposomal anthracyclines in development may be well tolerated but their activity remains to be elucidated by clinical trials. The available data also suggest that liposomal anthracyclines have activity not only against tumor types with known sensitivity to conventional anthracyclines, but also potentially for tumors that are typically anthracycline-resistant. Despite the availability of clinical data from a wide variety of tumor types and patient populations, further studies of liposomal anthracycline therapy are needed to fully establish their safety, efficacy, and dosing in the treatment of these patients.

Original languageEnglish (US)
Pages (from-to)53-90
Number of pages38
JournalSeminars in Oncology
Volume31
Issue numberSUPPL. 13
DOIs
StatePublished - Dec 2004

Fingerprint

Phase II Clinical Trials
Clinical Trials, Phase I
Anthracyclines
Safety
Neoplasms
Daunorubicin
Cytotoxins
Therapeutics
Doxorubicin
Pharmacokinetics
Clinical Trials
liposomal doxorubicin

ASJC Scopus subject areas

  • Oncology

Cite this

Alberts, D. S., Muggia, F. M., Carmichael, J., Winer, E. P., Jahanzeb, M., Venook, A. P., ... Gabizon, A. A. (2004). Efficacy and safety of liposomal anthracyclines in Phase I/II clinical trials. Seminars in Oncology, 31(SUPPL. 13), 53-90. https://doi.org/10.1053/j.seminoncol.2004.08.010

Efficacy and safety of liposomal anthracyclines in Phase I/II clinical trials. / Alberts, David S; Muggia, Franco M.; Carmichael, James; Winer, Eric P.; Jahanzeb, Mohammad; Venook, Alan P.; Skubitz, Keith M.; Rivera, Edgardo; Sparano, Joseph A.; Dibella, Nicholas J.; Stewart, Simon J.; Kavanagh, John J.; Gabizon, Alberto A.

In: Seminars in Oncology, Vol. 31, No. SUPPL. 13, 12.2004, p. 53-90.

Research output: Contribution to journalArticle

Alberts, DS, Muggia, FM, Carmichael, J, Winer, EP, Jahanzeb, M, Venook, AP, Skubitz, KM, Rivera, E, Sparano, JA, Dibella, NJ, Stewart, SJ, Kavanagh, JJ & Gabizon, AA 2004, 'Efficacy and safety of liposomal anthracyclines in Phase I/II clinical trials', Seminars in Oncology, vol. 31, no. SUPPL. 13, pp. 53-90. https://doi.org/10.1053/j.seminoncol.2004.08.010
Alberts, David S ; Muggia, Franco M. ; Carmichael, James ; Winer, Eric P. ; Jahanzeb, Mohammad ; Venook, Alan P. ; Skubitz, Keith M. ; Rivera, Edgardo ; Sparano, Joseph A. ; Dibella, Nicholas J. ; Stewart, Simon J. ; Kavanagh, John J. ; Gabizon, Alberto A. / Efficacy and safety of liposomal anthracyclines in Phase I/II clinical trials. In: Seminars in Oncology. 2004 ; Vol. 31, No. SUPPL. 13. pp. 53-90.
@article{e9e6ba7f3d234b0499937e699b7bc92e,
title = "Efficacy and safety of liposomal anthracyclines in Phase I/II clinical trials",
abstract = "Preclinical studies have established the pharmacologic advantages of liposomal anthracyclines, including pharmacokinetic profiles after bolus dosing that resemble continuous infusion of conventional anthracyclines, increased drug concentrations in tumor cells compared with the surrounding tissues, and reduced toxicity relative to conventional anthracycline treatment. Based on these studies, many phase I and phase II clinical trials were conducted to assess the safety and potential activity of liposomal anthracyclines in the management of both solid and hematologic tumors. These studies provided valuable insight into the safety of pegylated liposomal doxorubicin (Doxil/Caelyx [PLD]), nonpegylated liposomal doxorubicin (Myocet [NPLD]), and liposomal daunorubicin (DaunoXome [DNX]) over a range of doses, either as single-agent therapy or in combination with other cytotoxic agents. Other liposomal anthracyclines in development may be well tolerated but their activity remains to be elucidated by clinical trials. The available data also suggest that liposomal anthracyclines have activity not only against tumor types with known sensitivity to conventional anthracyclines, but also potentially for tumors that are typically anthracycline-resistant. Despite the availability of clinical data from a wide variety of tumor types and patient populations, further studies of liposomal anthracycline therapy are needed to fully establish their safety, efficacy, and dosing in the treatment of these patients.",
author = "Alberts, {David S} and Muggia, {Franco M.} and James Carmichael and Winer, {Eric P.} and Mohammad Jahanzeb and Venook, {Alan P.} and Skubitz, {Keith M.} and Edgardo Rivera and Sparano, {Joseph A.} and Dibella, {Nicholas J.} and Stewart, {Simon J.} and Kavanagh, {John J.} and Gabizon, {Alberto A.}",
year = "2004",
month = "12",
doi = "10.1053/j.seminoncol.2004.08.010",
language = "English (US)",
volume = "31",
pages = "53--90",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "SUPPL. 13",

}

TY - JOUR

T1 - Efficacy and safety of liposomal anthracyclines in Phase I/II clinical trials

AU - Alberts, David S

AU - Muggia, Franco M.

AU - Carmichael, James

AU - Winer, Eric P.

AU - Jahanzeb, Mohammad

AU - Venook, Alan P.

AU - Skubitz, Keith M.

AU - Rivera, Edgardo

AU - Sparano, Joseph A.

AU - Dibella, Nicholas J.

AU - Stewart, Simon J.

AU - Kavanagh, John J.

AU - Gabizon, Alberto A.

PY - 2004/12

Y1 - 2004/12

N2 - Preclinical studies have established the pharmacologic advantages of liposomal anthracyclines, including pharmacokinetic profiles after bolus dosing that resemble continuous infusion of conventional anthracyclines, increased drug concentrations in tumor cells compared with the surrounding tissues, and reduced toxicity relative to conventional anthracycline treatment. Based on these studies, many phase I and phase II clinical trials were conducted to assess the safety and potential activity of liposomal anthracyclines in the management of both solid and hematologic tumors. These studies provided valuable insight into the safety of pegylated liposomal doxorubicin (Doxil/Caelyx [PLD]), nonpegylated liposomal doxorubicin (Myocet [NPLD]), and liposomal daunorubicin (DaunoXome [DNX]) over a range of doses, either as single-agent therapy or in combination with other cytotoxic agents. Other liposomal anthracyclines in development may be well tolerated but their activity remains to be elucidated by clinical trials. The available data also suggest that liposomal anthracyclines have activity not only against tumor types with known sensitivity to conventional anthracyclines, but also potentially for tumors that are typically anthracycline-resistant. Despite the availability of clinical data from a wide variety of tumor types and patient populations, further studies of liposomal anthracycline therapy are needed to fully establish their safety, efficacy, and dosing in the treatment of these patients.

AB - Preclinical studies have established the pharmacologic advantages of liposomal anthracyclines, including pharmacokinetic profiles after bolus dosing that resemble continuous infusion of conventional anthracyclines, increased drug concentrations in tumor cells compared with the surrounding tissues, and reduced toxicity relative to conventional anthracycline treatment. Based on these studies, many phase I and phase II clinical trials were conducted to assess the safety and potential activity of liposomal anthracyclines in the management of both solid and hematologic tumors. These studies provided valuable insight into the safety of pegylated liposomal doxorubicin (Doxil/Caelyx [PLD]), nonpegylated liposomal doxorubicin (Myocet [NPLD]), and liposomal daunorubicin (DaunoXome [DNX]) over a range of doses, either as single-agent therapy or in combination with other cytotoxic agents. Other liposomal anthracyclines in development may be well tolerated but their activity remains to be elucidated by clinical trials. The available data also suggest that liposomal anthracyclines have activity not only against tumor types with known sensitivity to conventional anthracyclines, but also potentially for tumors that are typically anthracycline-resistant. Despite the availability of clinical data from a wide variety of tumor types and patient populations, further studies of liposomal anthracycline therapy are needed to fully establish their safety, efficacy, and dosing in the treatment of these patients.

UR - http://www.scopus.com/inward/record.url?scp=19944411434&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19944411434&partnerID=8YFLogxK

U2 - 10.1053/j.seminoncol.2004.08.010

DO - 10.1053/j.seminoncol.2004.08.010

M3 - Article

VL - 31

SP - 53

EP - 90

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - SUPPL. 13

ER -